Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zenas Files China IND for mAb to Treat Thyroid Eye Disease

publication date: May 16, 2022

Zenas BioPharma filed a China IND for Phase I/II trials of a therapy for Thyroid Eye Disease (TED). Zenas is a Shanghai-Boston biopharma that specializes in immune-based therapies. ZB001 is a differentiated humanized mAb targeting insulin-like growth factor 1 receptor (IGF-1R) for TED, a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye. TED can cause double vision, pain and blindness. Zenas acquired greater China rights to ZB001 from Viridian along with other compounds targeting IGF-1R in non-oncology indications. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital